Overview
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Status:
No longer available
No longer available
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Criteria
Inclusion Criteria:- Older than 18 years the time of radiotracer administration
- Provides written informed consent
- Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age
must have a negative pregnancy test at screening/baseline
- Able to remain still for duration of each imaging procedure (about 30 minutes)
Exclusion Criteria:
- Less than 18 years-old at the time of radiotracer administration
- Pregnant or nursing
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious concurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.